Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by HighSkies2019on Oct 03, 2021 11:48pm
175 Views
Post# 33959592

R107 Mentioned !!!

R107 Mentioned !!!Abstract In the prevailing coronavirus disease-2019 (COVID-19) times, scientists are eager to develop vaccines against COVID-19, and careful measures are being taken to develop an effective drug. Meanwhile, several antiviral compounds have been repurposed for COVID-19 treatment, and drug repurposing has yielded satisfactory results. In the meantime, nitric oxide (NO) is also under clinical trials to find its potentiality as anticoronavirus. This work aims to describe the therapeutic potential of NO for the treatment of deadly COVID-19. The significance of NO in mitigating COVID-19-associated symptomatic complications has also been addressed. NO being a molecule of significant biological interest is naturally synthesized in mammals and is the first member of the gasotransmitters. Biosynthesis and biological target studies reveal that this molecule bears the potential to stabilize oxidation stress and on the other hand oxidation stress has been the major cause of co-morbidity deaths of COVID-19. NO has already been reported to be an effective anticorona (first strains of corona virus). Within the past two months there has been an increased focus on the potential of NO for treatment of coronavirus and COVID-19 infection. R-107 and COViNOX are the two famous forms of NO-based prodrugs under clinical investigation against COVID-19. Therefore, it is worth presenting a literature survey based on the view to find utility of this simple molecule in treating COVID-19, a possible mechanism of action against coronavirus and future perspectives entailed with the research. It also becomes fruitful to introduce the use of NO boosters and clinically approved NO-releasing compounds purposeful in supplying NO if its bioavailability is found to be less than the optimal level. So, the profound antiviral effects of NO against coronavirus, and also the role it plays in relieving symptomatic severity of COVID-19 are supportive of the fact to declare NO as a therapeutic option for this disease
<< Previous
Bullboard Posts
Next >>